GPCR · NASDAQ
Structure Therapeutics
Structure-based drug design targeting GLP-1 with oral small molecules competing with injectable peptides.
HQ South San Francisco, CA, USA
Market cap Small
Focus Oral small-molecule GLP-1 (peptide-adjacent)
Investor relations ↗Last updated:Jul 15, 2026Source:SEC EDGAR + company IRVerified:Reviewed against latest filingsData provider:PeptidePlanet Research
Overview
Pipeline programs
2Active trials
0Upcoming catalysts
0Indications
2ObesityType 2 Diabetes
AI research summary
Generated on demand from verified profile data.
The AI summarizer only sees the verified fields on this page. Every numbered citation maps to a source in the legend below.
Pipeline
Clinical trials
No trials linked to this sponsor in our dataset.
Upcoming catalysts
No scheduled catalysts on file for this company.
Timeline
Merged approvals, trial milestones, and catalysts. Newest first.
No dated events on file.
Verified sources
- [1]Structure Tx IR — Structure Therapeuticsretrieved 2026-07-15
- [2]SEC EDGAR — U.S. Securities and Exchange Commissionretrieved 2026-07-15
- [3]ClinicalTrials.gov — U.S. National Library of Medicineretrieved 2026-07-15
SEC filings search: EDGAR ↗